Distribution AgreementsAn exclusive distribution agreement for vamorolone has been established in Russia, allowing access to AGAMREE for Duchenne muscular dystrophy patients across the country.
Market ExpansionProgress in multiple key European territories is slated with initial sales expected in the Nordics and formal launches planned for Spain and Portugal, with ongoing pricing and reimbursement discussions in several regions.
Sales GrowthVamorolone direct sales growth is accelerating in Germany, with increasing use beyond the initial pediatric cohort and rising combination therapy with DUVYZAT™.